The overall goal of this initiative is to investigate the cellular uptake, trafficking, and sub-cellular localization of different classes and subtypes of nanoparticles (NPs) with well-defined physiochemical properties for the creation of a reference table that relates the sub-cellular distribution of NPs to their intrinsic physiochemical properties across a range of cell lines. The subcellular fate of NPs is relevant both in terms of the therapeutic efficacy and biosafety of the NPs. The effective impact of size, shape, charge, and chemical composition of nanomaterials, in the presence of serum opsonins, on both cellular entry and subsequent subcellular localization will be investigated. The expected outcome of this project is to create a reference table that accelerates the transition of nanomaterials from the bench to the clinic by rapidly expanding our knowledge of the effect of a material's intrinsic characteristics on its intracellular destination. The final product, a comprehensive table of NPs and their subcellular locations, will guide the future development of NP drug delivery systems for rapid expansion of biomedical applications, including cancer therapy, cardiovascular imaging, and gene therapy.

Public Health Relevance

What this project seeks to deliver is a multi-dimensional reference table that relates the subcellular distribution and toxicity of NPs to their intrinsic physiochemical properties across a range of diverse cells and cell lines. It is our hope that the data generated from this project will serve as a resource for future research and encourage model development and new insights into nanotechnologies for imaging and drug delivery.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
High Impact Research and Research Infrastructure Programs (RC2)
Project #
1RC2GM092599-01
Application #
7854854
Study Section
Special Emphasis Panel (ZGM1-CBB-4 (MP))
Program Officer
Lewis, Catherine D
Project Start
2009-09-30
Project End
2011-08-31
Budget Start
2009-09-30
Budget End
2010-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$1,513,417
Indirect Cost
Name
University of Texas Health Science Center Houston
Department
Biomedical Engineering
Type
Schools of Medicine
DUNS #
800771594
City
Houston
State
TX
Country
United States
Zip Code
77225
Rupaimoole, R; Ivan, C; Yang, D et al. (2016) Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene 35:4312-20
McConnell, Kellie I; Shamsudeen, Sabeel; Meraz, Ismail M et al. (2016) Reduced Cationic Nanoparticle Cytotoxicity Based on Serum Masking of Surface Potential. J Biomed Nanotechnol 12:154-64
Kanlikilicer, Pinar; Rashed, Mohammed H; Bayraktar, Recep et al. (2016) Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. Cancer Res 76:7194-7207
Gonzalez-Villasana, Vianey; Fuentes-Mattei, Enrique; Ivan, Cristina et al. (2015) Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clin Cancer Res 21:2127-37
Kang, Shin-Ae; Hasan, Nafis; Mann, Aman P et al. (2015) Blocking the adhesion cascade at the premetastatic niche for prevention of breast cancer metastasis. Mol Ther 23:1044-1054
Ozcan, Gulnihal; Ozpolat, Bulent; Coleman, Robert L et al. (2015) Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 87:108-19
Wen, Yunfei; Zand, Behrouz; Ozpolat, Bulent et al. (2014) Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 7:488-500
Wu, Sherry Y; Lopez-Berestein, Gabriel; Calin, George A et al. (2014) RNAi therapies: drugging the undruggable. Sci Transl Med 6:240ps7
Gonzalez-Villasana, Vianey; Rodriguez-Aguayo, Cristian; Arumugam, Thiruvengadam et al. (2014) Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. Mol Cancer Ther 13:2583-94
Matsuo, Koji; Nishimura, Masato; Komurov, Kakajan et al. (2014) Platelet-derived growth factor receptor alpha (PDGFR?) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol 132:166-75

Showing the most recent 10 out of 86 publications